Henlius has been Listed on Hong Kong Stock Exchange

On September 25, 2019, Shanghai Henlius Biotech, Inc. (2696.hk) was officially listed on the Hong Kong stock exchange, co-sponsored by CICC, Merrill Lynch, CMBI, Fosun Hani and Citi Bank, and advised by UBS.

Before the listing, Staidson Zhejiang, a wholly-owned subsidiary of Staidson (Beijing) Biopharmaceuticals Co., LTD., planned to use its own fund of 10 million dollars to subscribe for the initial public offering shares of Henlius.

Henlius has issued 64,695,400 H shares, priced at 49.6 Hong Kong dollars per share, and officially listed on September 25, 2019. The final number of shares allocated to the public offering was 6.4696 million shares, accounting for 10% of the total number of shares offered.

The net proceeds from this fundraising are approximately 3,963 million Hong Kong dollars, about 40% of which will be used for ongoing clinical trials, regulatory filings, and registration of core products. 15% of this fund will be used for other biosimilar drugs, including HLX12, HLX11, and HLX14. 35% of this fund will be used for clinical trials of bioinnovative drugs, regulatory filings and registration, and the development of combined Immuno-oncology therapies. 10% of this fund will be used for operation and general purposes.

Henlius is a leading biopharmaceutical company in China with the vision to offer high-quality, affordable and innovative biologics for patients worldwide with a focus on oncology and autoimmune diseases. Since its inception in 2010, Henlius has built an integrated and efficient global R&D platform with key facilities in Shanghai, Taipei, and California.

Starting from biosimilar, Henlius develops novel mAb products and immuno-oncology combination therapies with its own anti-PD-1 and PD-L1 mAbs as the backbone. The company has established a diversified product pipeline of biosimilars, bio-innovative drugs, and combination therapies, and has built an integrated platform covering the whole product lifecycle. 

China International Capital Corporation Limited (CICC) is China’s first joint-venture investment bank and an international best practices pioneer. Since CICC's inception in 1995, it has established a full-service business model offering investment banking, equities, FICC, wealth management, and investment management. Owing to its expertise in economics, industrial development, and the legal arena, as well as quality service, CICC has received numerous financial industry honors.

Citi provides consumers, corporations, governments, and institutions with a broad range of financial services and products. Citi uses sponsorships as a powerful tool that can build and reinforce itself as a world-class brand — borrowing equity to raise awareness, showcase products, and services while bringing current and future clients closer to the things that they care about.